Skip to main content

FDA approves Celltrion's biosimilar to Roche's Herceptin

The U.S. Food and Drug Administration on Friday approved South Korean drugmaker Celltrion Inc's biosimilar to Roche Holding AG's blockbuster breast cancer treatment, Herceptin.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.